valproic acid has been researched along with Liver Diseases in 61 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is an antiepileptic drug (AED) used for generalized and absence seizures." | 5.32 | Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. ( Abbott, F; Farrell, K; Gopaul, S, 2003) |
| "Clonazepam was ineffective in treating the seizures and, in high doses, seemed to exacerbate the porphyria." | 5.26 | Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. ( Bonkowsky, HL; Emery, S; Sinclair, JF; Sinclair, PR, 1980) |
| "We present three children with severe therapy-refractory epilepsy who tolerated valproate (VPA) well in various combinations with other antiepileptic drugs (AEDs) but developed typical VPA side effects in combination with topiramate (TPM)." | 3.71 | Topiramate enhances the risk of valproate-associated side effects in three children. ( Koelfen, W; König, S; Longin, E; Teich, M, 2002) |
| "The authors report a case of fatal hepatic failure in a 19-year old young man suffering from absence seizures and treated for two months with valproic acid (VPA)." | 3.69 | [Fatal hepatic necrosis during treatment with sodium valproate]. ( Benaguida, M; Chlihi, A; Miguil, M; Mjahed, K; Moutawakkil, S; Sarf, I, 1995) |
| "A female neonate, whose mother had been treated throughout pregnancy with valproic acid and phenytoin, showed evident signs of liver damage, confirmed by laboratory investigations and biopsy." | 3.67 | Congenital liver damage after treatment of mother with valproic acid and phenytoin? ( Felding, I; Rane, A, 1984) |
| "Carnitine is an amino acid derivative that is an essential cofactor in the beta-oxidation of fatty acids." | 2.45 | Carnitine in the treatment of valproic acid-induced toxicity. ( Hantson, P; Lheureux, PE, 2009) |
| " These deal mainly with biochemical systems that are known to be affected by VPA, or with the possible idiosyncratic production of toxic VPA metabolites, especially delta 4-VPA." | 2.38 | Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. ( Levy, RH; Stephens, JR, 1992) |
| "Anticonvulsant therapy was among the first areas to benefit from clinical pharmacokinetic studies." | 2.35 | Clinical pharmacokinetics of anticonvulsants. ( Dam, M; Hvidberg, EF, 1976) |
| "The aim of this study was to investigate the relationship between hepatotoxicity, levels of glucuronide conjugates of valproic acid (VPA), and the toxic metabolites of VPA (4-ene VPA and 2,4-diene VPA)." | 1.35 | The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid. ( Baek, DJ; Chung, BC; Jung, BH; Kim, BJ; Lee, MS; Lee, YJ; Shin, KJ, 2009) |
| "Valproic acid (VPA) is an antiepileptic drug (AED) commonly used for generalized and focal epilepsies." | 1.33 | Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. ( Borusiak, P; Boxtermann, W; Brückner, R; Buesing, D; Degen, I; Degenhardt, V; Fitzek, S; Gerstner, T; Haensch, CA; Hanusch, R; Hartmann, M; Häussermann, P; Hoppen, T; Jungck, A; Kasper, JM; Kluger, G; Knapp, R; Koenig, SA; Korenke, GC; Kuhn, H; Lindmayer, F; Longin, E; Müller-Deile, A; Oehring, R; Richard, HH; Samii, K; Seitz, R; Specht, U; Weber, Y; Weidner, B, 2006) |
| "Valproic acid (VPA) is an antiepileptic drug (AED) used for generalized and absence seizures." | 1.32 | Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. ( Abbott, F; Farrell, K; Gopaul, S, 2003) |
| "A 6-month-old girl developed West syndrome and it remitted in association with valproate-induced hepatic dysfunction." | 1.31 | Remission of West syndrome associated with valproate hepatotoxicity. ( Go, T, 2002) |
| " The pathogenesis of VPA hepatotoxicity is unclear but may relate to the accumulation of a toxic metabolite of VPA which impairs fatty-acid oxidation." | 1.28 | The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. ( Applegarth, DA; Appleton, RE; Davidson, AG; Dimmick, JE; Farrell, K; Wong, LT, 1990) |
| " By analogy with certain spontaneous and acquired human disorders of branched chain amino acid metabolism, it is suggested that valproate-associated hepatotoxicity may represent the consequences of a valproate overload on a limited mitochondrial beta-oxidation capacity, causing accumulation of a toxic product of endogenous branched chain amino acid metabolism." | 1.28 | Valproate metabolism during hepatotoxicity associated with the drug. ( Dickinson, RG; Dunstan, PR; Eadie, MJ; MacLaughlin, D; McKinnon, GE, 1990) |
| "Clonazepam was ineffective in treating the seizures and, in high doses, seemed to exacerbate the porphyria." | 1.26 | Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. ( Bonkowsky, HL; Emery, S; Sinclair, JF; Sinclair, PR, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (42.62) | 18.7374 |
| 1990's | 17 (27.87) | 18.2507 |
| 2000's | 15 (24.59) | 29.6817 |
| 2010's | 3 (4.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walker, V | 1 |
| Stevens, CE | 1 |
| Turner, Z | 1 |
| Kossoff, EH | 1 |
| Lheureux, PE | 1 |
| Hantson, P | 1 |
| Lee, MS | 1 |
| Lee, YJ | 1 |
| Kim, BJ | 1 |
| Shin, KJ | 1 |
| Chung, BC | 1 |
| Baek, DJ | 1 |
| Jung, BH | 1 |
| LaBuzetta, JN | 1 |
| Yao, JZ | 1 |
| Bourque, DL | 1 |
| Zivin, J | 1 |
| Kreher, U | 1 |
| Darius, J | 1 |
| Wien, F | 1 |
| Gopaul, S | 1 |
| Farrell, K | 2 |
| Abbott, F | 1 |
| Foroughinia, F | 1 |
| Sabayan, B | 1 |
| Koenig, SA | 1 |
| Buesing, D | 1 |
| Longin, E | 2 |
| Oehring, R | 1 |
| Häussermann, P | 1 |
| Kluger, G | 1 |
| Lindmayer, F | 1 |
| Hanusch, R | 1 |
| Degen, I | 1 |
| Kuhn, H | 1 |
| Samii, K | 1 |
| Jungck, A | 1 |
| Brückner, R | 1 |
| Seitz, R | 1 |
| Boxtermann, W | 1 |
| Weber, Y | 1 |
| Knapp, R | 1 |
| Richard, HH | 1 |
| Weidner, B | 1 |
| Kasper, JM | 1 |
| Haensch, CA | 1 |
| Fitzek, S | 1 |
| Hartmann, M | 1 |
| Borusiak, P | 1 |
| Müller-Deile, A | 1 |
| Degenhardt, V | 1 |
| Korenke, GC | 1 |
| Hoppen, T | 1 |
| Specht, U | 1 |
| Gerstner, T | 1 |
| Jinjuvadia, K | 1 |
| Kwan, W | 1 |
| Fontana, RJ | 1 |
| Delima, SI | 1 |
| Walsh, LE | 1 |
| Golomb, MR | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Kochen, W | 1 |
| Schneider, A | 1 |
| Ritz, A | 1 |
| Ratnaike, RN | 1 |
| Buttery, JE | 1 |
| Hoffmann, S | 1 |
| Bruni, J | 1 |
| Albright, PS | 1 |
| Jeavons, PM | 1 |
| Felding, I | 1 |
| Rane, A | 1 |
| Isom, JB | 1 |
| Green, SH | 1 |
| Bonkowsky, HL | 1 |
| Sinclair, PR | 1 |
| Emery, S | 1 |
| Sinclair, JF | 1 |
| Bodensteiner, JB | 1 |
| Morris, HH | 1 |
| Golden, GS | 1 |
| Urien, S | 1 |
| Albengres, E | 1 |
| Tillement, JP | 1 |
| Thygesen, J | 1 |
| Boesen, F | 1 |
| Itoh, S | 1 |
| Yamaba, Y | 1 |
| Matsuo, S | 1 |
| Saka, M | 1 |
| Ichinoe, A | 1 |
| Asconapé, JJ | 1 |
| Penry, JK | 1 |
| Keene, DL | 1 |
| Humphreys, P | 1 |
| Carpenter, B | 1 |
| Fletcher, JP | 1 |
| Miguil, M | 1 |
| Chlihi, A | 1 |
| Mjahed, K | 1 |
| Sarf, I | 1 |
| Moutawakkil, S | 1 |
| Benaguida, M | 1 |
| Sobaniec-Lotowska, M | 1 |
| Sobaniec, W | 1 |
| Treem, WR | 1 |
| Löscher, W | 1 |
| Wahnschaffe, U | 1 |
| Hönack, D | 1 |
| Drews, E | 1 |
| Nau, H | 1 |
| Bryant, AE | 1 |
| Dreifuss, FE | 3 |
| Böhles, H | 1 |
| Sewell, AC | 1 |
| Wenzel, D | 1 |
| Sugimoto, T | 2 |
| Muro, H | 1 |
| Woo, M | 1 |
| Nishida, N | 1 |
| Murakami, K | 1 |
| Sobaniec-Lotowska, ME | 1 |
| Altunbaşak, S | 1 |
| Baytok, V | 1 |
| Tasouji, M | 1 |
| Hergüner, O | 1 |
| Burgut, R | 1 |
| Kayrin, L | 1 |
| Ballaban-Gil, K | 1 |
| Callahan, C | 1 |
| O'Dell, C | 1 |
| Pappo, M | 1 |
| Moshé, S | 1 |
| Shinnar, S | 1 |
| Hemingway, C | 1 |
| Leary, M | 1 |
| Riordan, G | 1 |
| Schlegal, B | 1 |
| Walker, K | 1 |
| Raza, M | 1 |
| al-Shabanah, OA | 1 |
| al-Bekairi, AM | 1 |
| Qureshi, S | 1 |
| Bohan, TP | 1 |
| Helton, E | 1 |
| McDonald, I | 1 |
| König, S | 2 |
| Gazitt, S | 1 |
| Scheffner, D | 2 |
| Cusmano, L | 1 |
| Li, S | 1 |
| Koch, G | 1 |
| Lott, RS | 1 |
| Helmboldt, KM | 1 |
| Madaras-Kelly, KJ | 1 |
| DeVivo, DC | 1 |
| Teich, M | 1 |
| Koelfen, W | 1 |
| Go, T | 1 |
| Anderson, GD | 1 |
| Klotz, U | 1 |
| Rapp, T | 1 |
| Müller, WA | 1 |
| Suchy, FJ | 1 |
| Balistreri, WF | 1 |
| Buchino, JJ | 1 |
| Sondheimer, JM | 1 |
| Bates, SR | 1 |
| Kearns, GL | 1 |
| Stull, JD | 1 |
| Bove, KE | 1 |
| Hvidberg, EF | 1 |
| Dam, M | 1 |
| Bicknese, AR | 1 |
| May, W | 1 |
| Hickey, WF | 1 |
| Dodson, WE | 1 |
| Stephens, JR | 1 |
| Levy, RH | 1 |
| Foster, GR | 1 |
| Goldin, RD | 1 |
| Freeth, CJ | 1 |
| Nieman, E | 1 |
| Oliveira, DB | 1 |
| Gilman, JT | 1 |
| Appleton, RE | 1 |
| Applegarth, DA | 1 |
| Dimmick, JE | 1 |
| Wong, LT | 1 |
| Davidson, AG | 1 |
| Eadie, MJ | 2 |
| McKinnon, GE | 1 |
| Dunstan, PR | 1 |
| MacLaughlin, D | 1 |
| Dickinson, RG | 2 |
| Langer, DH | 1 |
| Moline, KA | 1 |
| Maxwell, JE | 1 |
| Cotariu, D | 1 |
| Zaidman, JL | 1 |
| Shirkey, RJ | 1 |
| Jellett, LB | 1 |
| Kappatos, DC | 1 |
| Maling, TJ | 1 |
| Macdonald, A | 1 |
| Bassett, ML | 1 |
| Searle, J | 1 |
| Tyrer, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study[NCT05881928] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-07-25 | Not yet recruiting | ||
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
10 reviews available for valproic acid and Liver Diseases
| Article | Year |
|---|---|
Ammonia metabolism and hyperammonemic disorders.
Topics: Ammonia; Animals; Arginine; Biological Transport; Brain; Cell Membrane; Humans; Hyperammonemia; Hype | 2014 |
Carnitine in the treatment of valproic acid-induced toxicity.
Topics: Animals; Anticonvulsants; Antidotes; Carnitine; Chemical and Drug Induced Liver Injury; Energy Metab | 2009 |
Adult nonhepatic hyperammonemia: a case report and differential diagnosis.
Topics: Ammonia; Diagnosis, Differential; Humans; Hyperammonemia; Liver Diseases; Male; Metabolism, Inborn E | 2010 |
The clinical pharmacology of antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Drug Interactions; Ethosuximide; Female; Hal | 1984 |
Use of antiepileptic drugs in the presence of liver and kidney diseases: a review.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Half-Life; Humans; Kidney Diseases; Kinetics; Liver Diseas | 1982 |
Inherited and acquired syndromes of hyperammonemia and encephalopathy in children.
Topics: Ammonia; Child; Hepatic Encephalopathy; Humans; Liver Diseases; Metabolism, Inborn Errors; Reye Synd | 1994 |
Children versus adults: pharmacokinetic and adverse-effect differences.
Topics: Adolescent; Age Factors; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 2002 |
Clinical pharmacokinetics of anticonvulsants.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Anticonvulsants; Carbamazepine; Child; Clonazepam | 1976 |
Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
Topics: Ammonia; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Humans; Liver; Liver Diseases; | 1992 |
Valproic acid and the liver.
Topics: Amino Acids; Carnitine; Chemical and Drug Induced Liver Injury; Drug Interactions; Fatty Acids; Huma | 1988 |
1 trial available for valproic acid and Liver Diseases
| Article | Year |
|---|---|
The effect of carnitine supplementation in valproate-induced hyperammonaemia.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Chil | 1996 |
50 other studies available for valproic acid and Liver Diseases
| Article | Year |
|---|---|
Hepatic Dysfunction as a Complication of Combined Valproate and Ketogenic Diet.
Topics: Anticonvulsants; Combined Modality Therapy; Diet, Ketogenic; Drug Resistant Epilepsy; Female; Follow | 2016 |
The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
Topics: Administration, Oral; Alanine Transaminase; Animals; Anticonvulsants; Aspartate Aminotransferases; B | 2009 |
Abnormal alterations in the metabolic patterns of patients on valproate therapy.
Topics: Anticonvulsants; Chemical and Drug Induced Liver Injury; Humans; Infant; Liver Diseases; Male; Metab | 2002 |
Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA.
Topics: Acetylcysteine; Adolescent; Adult; Age Factors; Anticonvulsants; Chemical and Drug Induced Liver Inj | 2003 |
Ginkgo biloba extract: as a novel agent in prevention of valproic acid hepatotoxicity.
Topics: Anticonvulsants; Antioxidants; Free Radical Scavengers; Ginkgo biloba; Glutathione; Hepatocytes; Hum | 2007 |
Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Chil | 2006 |
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury.
Topics: Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Chemical and Drug Induced Li | 2007 |
Simultaneous toxicities in a child on multiple anticonvulsants.
Topics: Anticonvulsants; Bone Marrow; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child, P | 2008 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Sodium valproate and the liver.
Topics: Chemical and Drug Induced Liver Injury; Child; Epilepsy; Humans; Liver; Liver Diseases; Valproic Aci | 1980 |
Abnormal metabolism of valproic acid in fatal hepatic failure.
Topics: Chemical and Drug Induced Liver Injury; Child; Epilepsy, Tonic-Clonic; Humans; Liver Diseases; Male; | 1983 |
Blood ammonia measurement using a simple reflectometer.
Topics: Ammonia; Colorimetry; Humans; Liver Diseases; Quality Control; Valproic Acid | 1984 |
Non-dose-related side effects of valproate.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Aged; Child; Child, Preschool; Epilepsy; Fat Necrosi | 1984 |
Congenital liver damage after treatment of mother with valproic acid and phenytoin?
Topics: Adult; Epilepsy, Tonic-Clonic; Female; Humans; Infant; Liver; Liver Diseases; Maternal-Fetal Exchang | 1984 |
On the toxicity of valproic acid.
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Humans; Infant; | 1984 |
Sodium valproate and routine liver function tests.
Topics: Chemical and Drug Induced Liver Injury; Child; Epilepsy; Humans; Liver Diseases; Liver Function Test | 1984 |
Seizure management in acute hepatic porphyria: risks of valproate and clonazepam.
Topics: 5-Aminolevulinate Synthetase; Adult; Aminolevulinic Acid; Animals; Benzodiazepinones; Chick Embryo; | 1980 |
Asterixis associated with sodium valproate.
Topics: Adult; Female; Humans; Liver Diseases; Male; Muscular Diseases; Posture; Valproic Acid | 1981 |
Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.
Topics: Binding, Competitive; Blood Proteins; Drug Interactions; Fatty Acids, Nonesterified; Humans; Liver D | 1981 |
Adverse Drug Reactions Advisory Committee: ADRAC report for 1980.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Australia; Bronchial Spasm; Chemical and Drug Induced Live | 1982 |
2 cases of reversible liver lesion induced by valproate.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Liver Diseases; Valproic | 1982 |
Sodium valproate-induced liver injury.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases; Valproic Acid | 1982 |
Valproic acid producing a Reye-like syndrome.
Topics: Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; | 1982 |
[Fatal hepatic necrosis during treatment with sodium valproate].
Topics: Adult; Anticonvulsants; Chemical and Drug Induced Liver Injury; Fatal Outcome; Hepatic Encephalopath | 1995 |
Effect of chronic administration of sodium valproate on the morphology of the rat brain hemispheres.
Topics: Animals; Brain; Capillary Permeability; Chemical and Drug Induced Liver Injury; Culture Techniques; | 1993 |
Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting.
Topics: Animals; Chemical and Drug Induced Liver Injury; Fasting; Liver Diseases; Male; Random Allocation; R | 1993 |
Valproic acid hepatic fatalities. III. U.S. experience since 1986.
Topics: Adolescent; Adult; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1996 |
Valproate metabolites in high-dose valproate plus phenytoin therapy.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injur | 1996 |
Effects of long-term administration of the antiepileptic drug--sodium valproate upon the ultrastructure of hepatocytes in rats.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Liver; Liver Diseases; Male; Micro | 1997 |
Asymptomatic hyperammonemia in children treated with valproic acid.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Carnitine; Child; Child, Preschool; Epilepsy; Female; H | 1997 |
Complications of the ketogenic diet.
Topics: Adolescent; Carnitine; Child; Child, Preschool; Combined Modality Therapy; Epilepsy; Follow-Up Studi | 1998 |
The effect of carbamazepine and sodium valproate on the blood and serum values of children from a third-world environment.
Topics: Adolescent; Anemia; Anticonvulsants; Black People; Carbamazepine; Child; Child, Preschool; Developin | 1999 |
Pathomorphological changes in mouse liver and kidney during prolonged valproate administration.
Topics: Animals; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Epilepsy; Kidney; Kid | 2000 |
Effect of L-carnitine treatment for valproate-induced hepatotoxicity.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; | 2001 |
Retrospective evaluation of the effect of valproate therapy on transaminase elevations in patients with hepatitis C.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Chi-Squar | 2001 |
Effect of L-carnitine treatment for valproate-induced hepatotoxicity.
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Epilepsy; Humans; Liver Diseases | 2002 |
Topiramate enhances the risk of valproate-associated side effects in three children.
Topics: Affective Symptoms; Anticonvulsants; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinati | 2002 |
Remission of West syndrome associated with valproate hepatotoxicity.
Topics: Anticonvulsants; beta-Alanine; Chemical and Drug Induced Liver Injury; Electroencephalography; Femal | 2002 |
Disposition of valproic acid in patients with liver disease.
Topics: Adult; Biological Availability; Half-Life; Hepatitis; Humans; Kinetics; Liver Cirrhosis, Alcoholic; | 1978 |
Acute hepatic failure associated with the use of sodium valproate.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Epilepsy; Humans; Li | 1979 |
Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.
Topics: Brain; Chemical and Drug Induced Liver Injury; Diagnostic Errors; Diffuse Cerebral Sclerosis of Schi | 1992 |
Liver damage in long-term anticonvulsant therapy: a serological and histological study.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Chemical and Drug Induced Liver Injury; Drug Combinatio | 1991 |
Valproic acid hepatotoxicity in adults and older children.
Topics: Adult; Age Factors; Chemical and Drug Induced Liver Injury; Child; Humans; Liver Diseases; Valproic | 1991 |
The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects.
Topics: Chemical and Drug Induced Liver Injury; Humans; Infant; Liver Diseases; Male; Metabolism, Inborn Err | 1990 |
Valproate metabolism during hepatotoxicity associated with the drug.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Half-Life; Humans; Liver Diseases; Male; Midd | 1990 |
Valproic acid hepatic fatalities. II. US experience since 1984.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Live | 1989 |
Valproic acid hepatic fatalities: revised table.
Topics: Chemical and Drug Induced Liver Injury; Humans; Liver Diseases; Valproic Acid | 1989 |
Fatal liver failure in children on valproate.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Epilepsy; German | 1986 |
Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.
Topics: Adult; Blood Proteins; Erythrocytes; Humans; Kidney Diseases; Kinetics; Liver Diseases; Middle Aged; | 1985 |
Valproate hepatotoxicity: a review and report of two instances in adults.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Electroencephalography; Epilepsy; Humans; | 1985 |